Tirzepatide 40mg

Description

Tirzepatide 40mg — Research Dual Incretin Agonist (GLP-1 / GIP)

Tirzepatide 40mg is a high-concentration dual incretin research peptide that simultaneously activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Furthermore, this higher-dose formulation makes Tirzepatide 40mg particularly suitable for extended preclinical studies requiring greater compound availability.

Research Focus (Non-Clinical)

Researchers deploy to investigate advanced GLP-1R and GIPR dual-receptor co-activation mechanisms. In addition, preclinical models use this compound to examine glucose homeostasis, insulin sensitivity markers, and energy regulation endpoints at higher concentration ranges. Moreover, investigators actively study visceral adiposity reduction, lipid metabolism, and body composition changes under controlled laboratory conditions.

Product Specifications

Each vial contains 40mg of lyophilized, providing researchers with a larger quantity for long-term or multi-session studies. Therefore, Tirzepatide 40mg offers greater flexibility for complex experimental protocols. Additionally, NUPEPS Peptides verifies every batch for identity and purity through rigorous third-party lab testing.

Regulatory & Use

Tirzepatide 40mg is strictly for laboratory research purposes only. It is not intended for human, veterinary, or diagnostic use. Qualified researchers can review the full COA Library for complete batch-specific purity data.